Companies sponsors |
Roche (pralsetinib) |
Others |
Department of Health and Social care |
|
NHS England |
|
Welsh Government |
Patient carer groups |
Roy Castle Lung Cancer Foundation |
Professional groups |
Association of Cancer Physicians |
|
British Thoracic Oncology Group |
|
British Thoracic Society |
|
Royal College of Pathologists |
|
Royal College of Physicians |
Comparator companies |
Accord Healthcare - not participating |
|
Actavis UK - not participating |
|
Aspire Pharma - not participating |
|
Boehringer Ingelheim - not participating |
|
Bristol-Myers Squibb Pharmaceuticals - not participating |
|
Celgene - not participating |
|
Consilient Health Ltd - not participating |
|
Dr Reddy’s Laboratories - not participating |
|
Eli Lilly (selpercatinib, pemetrexed) |
|
Fresenius Kabi - not participating |
|
Fresenius Kabi Oncology - not participating |
|
Hospira UK - not participating |
|
Medac GmbH - not participating |
|
Merck Sharp & Dohme (pembrolizumab) |
|
Organon Pharma (UK) - not participating |
|
Pfizer (bevacizumab, carboplatin, cisplatin, docetaxel, gemcitabine, paclitaxel) |
|
Pierre Fabre - not participating |
|
Roche (atezolizumab, bevacizumab) |
|
Sandoz - not participating |
|
Sanofi - not participating |
|
Seacross pharmaceuticals - not participating |
|
Sun Pharma - not participating |
|
Teva UK - not participating |
General commentators |
All Wales Therapeutic and Toxicology Centre |
|
British National Formulary |
|
Department of Health, Social Services and Public Safety for Northern Ireland |
|
Healthcare Improvement Scotland |
|
Medicines and Healthcare Products Regulatory Agency |
|
Welsh Health Specialised Services Committee |
Relevant research groups |
Institute of Cancer Research |